MarginScan™: Real-Time Surgical Margin Assessment

MarginScan™ enables rapid, non-destructive assessment of cancer margins during surgical excision. Using spectral bioimpedance and AI/ML, MarginScan detects and localizes residual cancer in seconds, without requiring frozen sectioning or dedicated pathology resources.

MarginScan supports healthy tissue–sparing surgery, improves workflow predictability, and can reduce recurrence—while preserving tissue for standard pathological analysis when desired.

MarginScan™ is manufactured by PHC Group, a division of PHC Holdings (TSE: 6523).

MarginScan is not FDA cleared or approved. The first clearance, for skin cancer, is targeted for early 2027.